ReviewMolecular psychiatry2024
Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential.
Review in Molecular psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 33 citations in OpenAlex.
- Psilocybin restores behavior and 5-HTCell reports. Medicine · 2026Article
- Psychedelics and Autism Therapy: A Review of Current Research and Future Directions.Current issues in molecular biology · 2026Review
- Kynurenine pathway dysregulation in major depressive disorder: the convergence of excitotoxicity, neuroinflammation, and oxidative stress.Journal of neuroinflammation · 2026Review
- A Virtual Clinical Trial of Psychedelics to Treat Patients With Disorders of Consciousness.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Psilocybin-containing mushroom-assisted psychotherapy is associated with sustained psychological and somatic improvements: two case studies from Jamaica.Frontiers in psychiatry · 2026Article
- Exploring the potential of psychedelics in brain injury recovery: a thematic analysis of participant narratives.Frontiers in neurology · 2026Article
- Psilocybin-assisted physiotherapy for refractory motor functional neurological disorder: protocol for a randomised dose-comparison pilot study.Acta neuropsychiatrica · 2025Article
- Psychedelics in the Treatment of Neurologic and Psychiatric Disorders: Coincidence or a New Point of View.Molecular neurobiology · 2025Review
- Exploring the therapeutic role of Moringa oleifera in neurodegeneration: antioxidant, anti-inflammatory, and neuroprotective mechanisms.Inflammopharmacology · 2025Review
- Exploring the Therapeutic Effects of Psychedelics Administered to Military Veterans in Naturalistic Retreat Settings.Brain and behavior · 2025Article
- Unveiling GABA and Serotonin Interactions During Neurodevelopment to Re-Open Adult Critical Periods for Neuropsychiatric Disorders.International journal of molecular sciences · 2025Review
- The Potential Role of Psilocybin in Traumatic Brain Injury Recovery: A Narrative Review.Brain sciences · 2025Review
- Can the gut-brain axis provide insight into psilocybin's therapeutic value in reducing stress?Neurobiology of stress · 2025Review
- Exploring the Therapeutic Potential of Psychedelics in Chronic Pain Management: A New Frontier in Medicine.Neuroscience bulletin · 2025Article
- Noncanonical feedback loop between "RIP3-MLKL" and "4EBP1-eIF4E" promotes neuronal necroptosis.MedComm · 2025Article
- Advancements in the investigation of gut microbiota-based strategies for stroke prevention and treatment.Frontiers in immunology · 2025Review
- Improved mental health outcomes and normalised spontaneous EEG activity in veterans reporting a history of traumatic brain injuries following participation in a psilocybin retreat.Frontiers in psychiatry · 2025Article
- Factors Influencing Return to Work Among Women With Acquired Brain Injury.Occupational therapy international · 2025Article
- Dose-dependent changes in global brain activity and functional connectivity following exposure to psilocybin: a BOLD MRI study in awake rats.Frontiers in neuroscience · 2025Article
- The New Frontier in Neurotherapeutics: From Brain Stimulation to Novel Psychotropics.ACS medicinal chemistry letters · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acquired brain injury (ABI), such as traumatic brain injury and stroke, is a leading cause of disability worldwide, resulting in debilitating acute and chronic symptoms, as well as an increased risk of developing neurological and neurodegenerative disorders. These symptoms can stem from various neurophysiological insults, including neuroinflammation, oxidative stress, imbalances in neurotransmission, and impaired neuroplasticity. Despite advancements in medical technology and treatment interventions, managing ABI remains a significant challenge. Emerging evidence suggests that psychedelics may rapidly improve neurobehavioral outcomes in patients with various disorders that share physiological similarities with ABI. However, research specifically focussed on psychedelics for ABI is limited. This narrative literature review explores the neurochemical properties of psychedelics as a therapeutic intervention for ABI, with a focus on serotonin receptors, sigma-1 receptors, and neurotrophic signalling associated with neuroprotection, neuroplasticity, and neuroinflammation. The promotion of neuronal growth, cell survival, and anti-inflammatory properties exhibited by psychedelics strongly supports their potential benefit in managing ABI. Further research and translational efforts are required to elucidate their therapeutic mechanisms of action and to evaluate their effectiveness in treating the acute and chronic phases of ABI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.